moderna-alumni
(2)
Kevin Walton
Kevin Walton is the Chief Executive Officer and Board Director of Baseimmune, a London-based biotech using AI and computational protein design to build next-generation vaccines and active immunotherapies. He joined in 2024 after a career in biotech corporate development and dealmaking at Moderna, StrideBio, Curis and G1 Therapeutics, and is steering the company beyond infectious-disease vaccines into chronic diseases, starting with a lead fibrosis program in idiopathic pulmonary fibrosis.
Axelyf
Axelyf is a Brookline, Massachusetts biotech (with an R&D subsidiary in Iceland) building next-generation lipid nanoparticle delivery systems for RNA medicines. Founded by former Moderna drug-delivery leaders, it pairs a proprietary AXL ionizable-lipid library with an AI model called ANNA to make RNA and gene-editing payloads reach the right tissue with higher potency and less toxicity. In mouse liver studies its AXL LNPs showed roughly 4-5x higher gene-editing efficiency than the LP-01 clinical benchmark at equivalent doses, without evidence of liver toxicity. The company closed $2.6M in seed funding in August 2025 to push its lead autoimmune program and lipid library toward preclinical and non-human-primate studies.